Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
UCART22 is a preparation of allogeneic T-cells expressing a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 3763).
|DrugClasses||CD22 Immune Cell Therapy 10|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|